

Date: 23 August 2022

The Board of Directors

China NT Pharma Group Company Limited
28th Floor, The Wellington,
198 Wellington Street, Sheung Wan,
Hong Kong

Dear Sirs/Madams,

RE: China NT Pharma Group Company Limited,
VERY SUBSTANTIAL ACQUISITION IN RELATION TO THE LICENSING OF
COMMERCIALISATION RIGHTS


We refer to the circular issued by China NT Pharma Group Company Limited, (the “**Company**”, together with its subsidiaries, the “**Group**”) dated 23 August 2022 (the “**Circular**”) relating to the captioned matter. Capitalised terms used herein shall have the same meanings as those defined in the Circular unless otherwise defined.

We hereby give our formal consent, and confirm that we have not withdrawn our consent, to the issue of the Circular with the inclusion of the Valuation Report and references to our name in the form and context in which they respectively appear.

We hereby further grant our consent to the Valuation Report and this letter being made available for display as described in Appendix VI to the Circular.

We also confirm that as at the Latest Practicable Date, we did not have: (a) any direct or indirect interest in any assets which have been, since 31 December 2021 (being the date to which the latest published audited consolidated financial statements of the Group were made up) acquired or disposed of by or leased to any member of the Group, or were proposed to be acquired or disposed of by or leased to any member of the Group; or (b) any beneficial interests in the share capital of any member of the Group, or any right (whether legally enforceable or not) to subscribe for or nominate persons to subscribe for securities in any member of the Group.

Yours faithfully,
For and on behalf of
CHFT Advisory and Appraisal Limited



Ross Wang, CFA
Director